NeoGenomics offers lab services for oncology clinical trials
For current Clarient clients only, access your Clarient resources here.
August 29 - September 2, 2016 - Boston, MA
SP142 for bladder cancer now available
The July-December 2016 self-assessment for our tech-only FISH clients is ready.
Ventana PD-L1 (SP142) Assay, an FDA approved complementary diagnostic in metastatic urothelial carcinoma.
Comprehensive detection of sarcoma transocations
by next-gen sequencing to enhance diagnosis,
subclassification, and treatment
Sarcoma Fusion Profile
Targeted next-gen sequencing panel that detects
significant translocations in the genes NTRK1,
NTRK3, and RET
NGS Thyroid Fusion Profile